Pelvital, a privately held medical device company that has developed Flyte, a clinically proven, FDA-cleared, non-surgical treatment for female stress urinary incontinence (SUI), announced today that Ryan Willemsen has been appointed Chief Operations Officer.
In this role, Willemsen will be responsible for leading the operations of Pelvital with a focus on market adoption of Flyte, building a global sales and distribution capability, expanding operational infrastructure of Pelvital, and bringing next generation products to the market. Ryan joined Pelvital in December of 2020 as the Chief Commercial Officer where he has focused on developing an understanding of the commercial needs for an at-home therapy such as Flyte and implementing strategies to assure the adoption of Flyte. With more than 14 years of medical technology leadership experience, including 8 years in pelvic health, Willemsen has experience at developing new markets, bringing new products to market, and leading successful commercial organizations.
“We are excited to have Ryan expanding his influence in developing and growing Pelvital. His proven track record of executive leadership will not only help us develop the market for Flyte but will help us prepare the company for expansion into other applications of our unique mechanotherapy technology,” said Dale Wahlstrom Co-Founder and CEO of Pelvital. “His success in his past roles has helped him to rapidly grasp the challenges of people suffering from Stress Urinary Incontinence and will be invaluable in achieving Pelvital’s mission to help people suffering from skeletal muscle conditions.”
Willemsen’s 14 years of experience at Medtronic include executive leadership positions in marketing, strategy, business development and finance. While at Medtronic, Ryan developed and led strong teams to drive growth in new and developing global medical device markets.
“I am very excited to be part of the Pelvital team and thrilled to be part of bringing a proven new technology platform to the market,” said Willemsen. “The clinical data, and the response of patients who have used the product since our market release in January, have confirmed that mechanotherapy really works to treat SUI. We will continue our focus on market adoption to treat SUI but will begin the process of expanding the application of the technology to other unmet needs. Our journey is just beginning.”